title: Nab-paclitaxel in the treatment of metastatic breast cancer: a comprehensive review.
abstract: The novel paclitaxel formulation (nanoparticle albumin-bound [nab] paclitaxel (Abraxane(®)) has recently been approved by the US FDA for treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months after adjuvant chemotherapy. Apart from its superior efficacy, as demonstrated in the pivotal Phase III study, less toxicity compared with the traditional solvent-containing paclitaxel (Taxol(®)) seems to contribute to its favorable therapeutic index. While approved as a single agent, nab-paclitaxel may prove more effective in combination with either biologic agents and/or other cytotoxic chemotherapeutic agents, as summarized in this article.
authors: Department of Medicine, Division of Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami, Leonard M Miller School of Medicine, 1475 NW 12th Avenue, Miami, FL 33136, USA.
authors: Alberto J
authors: AJ
authors: Montero
authors: Betsy
authors: B
authors: Adams
authors: C Marcela
authors: CM
authors: Diaz-Montero
authors: Stefan
authors: S
authors: Glück
mesh_terms: D000418:Albumins / Q000627:therapeutic use*; D000818:Animals; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D002626:Chemistry, Pharmaceutical; D017326:Clinical Trials, Phase III as Topic / Q000379:methods; D005260:Female; D006801:Humans; D009362:Neoplasm Metastasis / Q000188:drug therapy* / Q000473:pathology; D017239:Paclitaxel / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: C520255:130-nm albumin-bound paclitaxel; D000418:Albumins; D017239:Paclitaxel